Experience

Davis Polk is advising Aetna Inc. in connection with the sale by Aetna and Humana Inc. of certain of their respective Medicare Advantage assets to Molina Healthcare, Inc. for a total…

Davis Polk advised the joint book-running managers in connection with the $120 million follow-on offering of common stock of Global Blood Therapeutics, Inc. Global Blood’s common stock is…

Davis Polk advised the joint book-running managers and representatives of the underwriters in the $182.2 million initial public offering by BeiGene, Ltd. of 7,590,000 American Depositary…

Davis Polk is advising Biotie Therapies Corp. in connection with its combination agreement with Acorda Therapeutics, Inc. where Acorda will make a public tender offer in Finland and the…

Davis Polk advised the joint book-running managers in connection with the $138 million initial public offering of common stock of Global Blood Therapeutics, Inc. Global Blood’s common stock…

Davis Polk advised the initial purchasers in connection with a Rule 144A/Regulation S offering by Hologic, Inc. of $1 billion aggregate principal amount of its 5.250% senior notes due 2022…

Davis Polk advised the underwriters in connection with the $72.5 million U.S. initial public offering of 5,175,000 common shares of Cynapsus Therapeutics Inc., including 675,000 common…

Davis Polk advised the administrative agent in connection with the refinancing of Hologic, Inc.’s existing senior secured credit facilities with a $1.5 billion term loan facility and a $1…